Quadrature Capital Ltd Sells 35,589 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Quadrature Capital Ltd lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 65.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,536 shares of the medical research company's stock after selling 35,589 shares during the quarter. Quadrature Capital Ltd's holdings in IQVIA were worth $4,390,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in IQVIA during the third quarter valued at approximately $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA in the third quarter valued at approximately $28,000. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the second quarter valued at approximately $27,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter valued at approximately $29,000. Finally, International Assets Investment Management LLC acquired a new position in shares of IQVIA in the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IQV. Robert W. Baird reduced their price target on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Royal Bank of Canada restated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a report on Wednesday. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Stock Performance

Shares of IQV traded up $2.70 during trading hours on Friday, hitting $202.63. The company had a trading volume of 1,388,125 shares, compared to its average volume of 1,180,243. The firm has a market cap of $36.78 billion, a price-to-earnings ratio of 26.59, a PEG ratio of 2.06 and a beta of 1.49. The business has a fifty day moving average of $215.18 and a 200-day moving average of $225.14. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.